Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity

Exp Anim. 2018 Nov 1;67(4):493-500. doi: 10.1538/expanim.18-0042. Epub 2018 Jun 22.

Abstract

This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolimus (mTORi), and everolimus plus cisplatin (mTORi+Cis). Mice in the Cis and mTORi+Cis groups were intraperitoneally injected with 2 mg/kg of cisplatin for 15 d. Mice in the mTORi and mTORi+Cis groups were orally administered 2.5 mg/kg of everolimus for 29 d, from one week before the first cisplatin injection to one week after the last cisplatin injection. Histological examinations were performed 24 h after the last everolimus administration. The primordial, primary, and antral follicles were significantly depleted in the Cis group compared with that in the control group, confirming the gonadotoxicity of cisplatin. The number of primordial, secondary, and antral follicles was significantly higher in the mTORi+Cis group than in the Cis group, thereby displaying the effect of mTORi-treatment on ovarian protection. Primordial, secondary, and antral follicle counts were similar in the mTORi+Cis and the control groups. The results of this study indicate a protective effect of an mTOR inhibitor against cisplatin chemotherapy-induced gonadotoxicity in the ovarian reserve in an in vivo mouse model.

Keywords: chemotherapeutic agent-induced gonadotoxicity; cisplatin; fertility preservation; mechanistic target of rapamycin inhibitor; ovarian protection.

MeSH terms

  • Administration, Ophthalmic
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / toxicity*
  • Cisplatin / administration & dosage
  • Cisplatin / toxicity*
  • Drug Therapy, Combination
  • Everolimus / administration & dosage*
  • Everolimus / pharmacology*
  • Female
  • In Vitro Techniques
  • Injections, Intraperitoneal
  • Mice, Inbred C57BL
  • Ovarian Follicle / drug effects*
  • Ovarian Follicle / pathology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Everolimus
  • TOR Serine-Threonine Kinases
  • Cisplatin